<DOC>
	<DOCNO>NCT01130480</DOCNO>
	<brief_summary>COMPASS status intervention study self-monitoring blood glucose ( SMBG ) type 2 diabetic patient insulin treatment . This multi-centre , open-label prospective study ass use frequency SMBG blood glucose control influence factor help Accu-Chek Integra glucometer . Patients type 2 diabetes mellitus receive 3 month insulin therapy eligible participate study . The anticipated duration study 6 month .</brief_summary>
	<brief_title>Accu-Chek missiOn : SMBG Patients With diAbetes inSulin Study ( COMPASS ) - Multiple Center , Open , Non-randomized Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type II diabetes mellitus patient receive insulin treatment 3 month Patients willing sign write informed consent form Patients meet criterion first crosssectional investigation HbA1c &lt; 7 % receive second crosssectional investigation Patients unable unwilling comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>